AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

A novel diagnostic method and therapeutic treatment of acute pulmonary inflammation

Summary

Researchersat OSU have discovered a novel antibody that could constitute a new therapeuticmethod to restrict the pathogenesis of ALI/ARDS. In a clinically relevantanimal model of ALI, a novel monoclonal antibody discovered by the researcherssignificantly inhibits neutrophil influx into alveolar space. Becauseneutrophil inflammation is central to development of ALI, this antibody mayprove to be the therapeutic agent that is greatly needed for ALI/ARDS patients.Moreover, this anitibody could be used as a novel diagnostic marker forALI/ARDS. This is critical because current diagnosis of ALI/ARDS is performedby the presence of non-cardiogenic pulmonary edema and respiratory failure,which are non-specific measures subject to inter-observer variability.

Technology Benefits

· Enables earlydetection of ALI/ARDS· Novel treatmentmethod to reduce severity of ALI/ARDS

Technology Application

· Quantitativediagnostic tool for ALI/ARDS· Method oftreatment for ALI/ARDS· Treatment forother inflammatory diseases, especially lung

Detailed Technology Description

None

Country/Region

USA

For more information, please click Here